Home / Transcripts / Ashland Inc. (ASH) · November 5, 2025

Ashland Inc. (ASH) Earnings Call Transcript

November 5, 2025

New York Stock Exchange US Materials Chemicals earnings 79 min

Earnings Call Speaker Segments

Sandy Klugman executive
#1

Thanks, and good day to all of you. It's a pleasure to have you join us for Ashland's conference call and webcast covering results from the fourth quarter of fiscal year 2025. I'm Sandy Klugman, and I've come aboard Ashland not long ago in the position of Director of Investor Relations. It's thrilling for me to take on this responsibility during such a crucial period for Ashland and those with a stake in the company, and I'm eager to engage with lots of you over the coming months. With me today are Guillermo Novo, our Chair and CEO; William Whitaker, our CFO; plus the leaders of our business units: Alessandra Fassin, who oversees Life Sciences and Intermediates; Jim Minicucci, who oversees Personal Care; and Dago Caceres, who oversees Specialty Additives. Be aware that slides will be shown throughout this call. We invite you to view the webcast materials, which can be found at ashland.com within the Investor Relations section. Kindly navigate to Slide 2. I'd like to remind you that this presentation includes forward-looking statements about our fiscal 2026 outlook and other topics, all of which are laid out on Slide 2 and within our Form 10-K. Such statements carry risks and uncertainties that might lead future outcomes to vary materially from the projections shared today; we consider these statements to rest on sensible assumptions, yet we cannot guarantee that these expectations will come to pass; additionally, we'll mention some adjusted financial metrics, covering both actual and projected figures, and these are non-GAAP measures; we offer these adjusted numbers so you can gain a fuller understanding of how our business is performing on an ongoing basis. Reconciliations to GAAP can be found on our website as well as in the appendix of these slides. At this point I'll pass things over to Guillermo so he can share his opening comments.

Guillermo Novo executive
#2

Thank you, Sandy, and hello to everyone who has joined us. I'm going to give you a look at how we performed in the fourth quarter, walk through our strategic priorities, and present our guidance for fiscal 2026. If you would please go to Slide 5. We'll start with a recap of how we've done recently. Ashland's results for the fourth quarter show the discipline we bring and our capacity to meet expectations even as macroeconomic difficulties persist. We held margins at a strong level and delivered revenue and EBITDA in line with what we had previously guided. Our ongoing emphasis on execution, together with momentum from our globalize and innovate initiatives, helped counterbalance pockets of competitive pressure and soft demand. Sales in Q4 came to $478 million, a decline of 8% compared with a year earlier, largely because of portfolio optimization initiatives. If you set those actions aside, sales were down 1%. Adjusted EBITDA reached $119 million, 4% lower than the prior year, and that figure includes an $11 million impact from portfolio optimization. Looking at it on a comparable basis, adjusted EBITDA rose 5%, with margins widening to approximately 25%. What matters is that these results capture the early gains from our strategic actions and put us in a good position to enhance performance. Please turn now to Slide 6. Let me take a moment to go over how each of our business units performed. Life Science turned in steady results, which shows the value of our sharper focus on higher-value pharma. Demand held up well, with ongoing strength in cellulosic excipients, tablet coatings and injectables. Nutrition did show some softness during the quarter, but the team recently won share gains that should support a return to growth next year. Our innovate and globalize strategies continue to underpin quality growth and durable margins. Personal Care posted broad-based gains across end markets and regions while keeping profitability strong. Disciplined execution and a sharper commercial focus are producing results even in a muted environment. Investments in bio-functional actives and microbial protection gained momentum, with both lines getting back to healthy growth in Q4. Specialty Additives performed well in a mixed market, lifting EBITDA on a quarter-over-quarter basis. Every end market other than coatings showed improvement, including performance specialties, construction and energy and resources. Those gains, however, were more than offset by softer coatings in China, India and Middle East and North America. We keep steering resources toward high-value applications, which strengthens our position ahead of a coatings recovery. Intermediates dealt with headwinds from lower pricing and production volumes, and that hurt profitability. The team is still focused on optimizing operations in a difficult market. Zooming out from the segments, I'd like to point out how our transformation efforts are shaping Ashland's path forward. Portfolio optimization and restructuring are finished, and the organization is now centered on consistent delivery. As we've said previously, roughly 85% of our portfolio serves consumer-facing end markets. Those areas are generally more stable and less sensitive to economic cycles, which offers a degree of consistency and resilience amid broader macroeconomic volatility. The $60 million manufacturing optimization program is aiding margins, although the timing of the P&L impact is later than we first anticipated. William will go through the drivers afterward; during the quarter, Life Science and Personal Care each posted EBITDA margins near or above 30%. Specialty Additives posted its strongest margins for the year, whereas Intermediates kept confronting pressure on margins in a tough market; looking at things on a comparable basis, adjusted EBITDA rose versus the prior year across every business unit apart from Intermediates. Our globalized platforms got back to healthy growth during Q4, and we beat the innovation targets we had set. To sum up, even though conditions outside the company stay unpredictable, we keep producing results by executing with discipline and staying clearly focused on our priorities. Thanks to our focused portfolio, cost actions that are picking up steam and growth initiatives that are gaining traction, Ashland is positioned well to deliver resilient long-term value. I would now like to hand the call over to William so he can give a more detailed review of the fourth quarter financial performance. William?

William Whitaker executive
#3

Thanks, Guillermo. If you could move to Slide 8. Revenue came in at $478 million, which is 8% lower than a year ago, and portfolio optimization moves made up $38 million of that decline. If you take out those actions, revenue was basically level, off just 1%, as demand stayed consistent across most regions. Personal Care gave us volume growth, which offset some weakness in Specialty Additives, and Life Sciences was unchanged. Overall pricing declined roughly 2%, driven largely by deliberate price moves in Life Sciences starting in Q2 and ongoing pressure in Intermediates. If you exclude Intermediates, pricing slipped only 1%, and currency gave us a small 1% boost. Adjusted EBITDA reached $119 million, which is a 4% drop versus the same period last year. Portfolio moves created an $11 million drag; however, leaving those out, underlying EBITDA rose 5%, which puts us back in growth territory on a comparable basis. Reduced SARD stemming from restructuring efforts helped expand margins, together with a better mix. Those benefits were partly offset by softer pricing and lower production volumes, though raw material costs held steady. Our adjusted EBITDA margin widened to 24.9%, an increase of 110 basis points compared with a year ago. That made this our strongest quarter of the year for profitability and right in line with the 25% long-term margin target we've set. Adjusted earnings per share, before acquisition amortization, came to $1.08, a 14% decline versus the previous year, hit disproportionately by a higher effective tax rate during the quarter. That rise comes from jurisdictional tax changes and only limited use of foreign tax credits; we anticipate an effective tax rate in the mid-20s for next year. We turned in yet another quarter of strong cash generation, with ongoing free cash flow of $52 million. That represents solid conversion of adjusted EBITDA, which speaks to how carefully we manage capital spending and working capital. Although Q4 ongoing free cash flow is lower than a year ago, mostly because of higher accounts receivable following strong September sales, it's still in line with what we've recently expected. As of quarter end, total liquidity was a bit above $800 million, which gives us ample flexibility. Net leverage came in at 2.9x, and thanks to the $103 million tax refund we got in October from the nutraceutical divestiture, net leverage now sits nearer the mid-2s. That leaves us well positioned to keep putting money into our strategic priorities while staying disciplined about capital allocation. Let's now hear from our business unit leaders, who can walk through segment performance in more detail. Alessandra, you have Life Sciences.

Alessandra Assis executive
#4

Thanks, William, and good morning to all of you. If you would, please go to Slide 9, where we cover Life Sciences. In the fourth quarter, Life Sciences sales came in at $173 million, which is a 10% drop versus last year. What drove that decrease was mainly the divestiture of the nutraceuticals business along with our exit from low-margin nutrition offerings. Looking at it on a comparable basis, sales were largely flat, slipping 2% year-over-year, and that reflects a combination of volume and price. Now to demand trends. In the majority of areas, Pharma held up well, with sales increasing by a low single-digit percentage compared to the prior year. That forward motion was driven by new products and appetite for high-value cellulosic excipients, along with ongoing expansion in our globally oriented business segments—tablet coatings and injectables—which fits our long-range strategy and growth targets. Conditions in Nutrition's end markets were weaker, though newly secured business should assist in bringing about a comeback to profitable growth during fiscal 2026. Regarding price, the prior-year challenges became less severe from one quarter to the next, and pricing was largely steady throughout the period. Currency movements provided a $3 million benefit to sales. Advancing drug development remains a core focus for us. Two examples: we introduced vialose sucrose, an excipient of high purity designed for injectable medicines, and we broadened our portfolio of low-nitrite excipients so customers can reduce nitrosamine exposure. Through these additions, Ashland shows it is dedicated to providing quality options that meet what the pharmaceutical sector needs as those needs change. Now let's discuss earnings. Adjusted EBITDA came in at $55 million, equal to a 32% margin, down 2% from the $56 million recorded a year earlier. That drop against the prior year is largely due to a $3 million effect tied to portfolio optimization moves, which repositioned this segment toward applications offering stronger returns. Taking that item out of the picture, adjusted EBITDA was up $2 million, as mix and a decrease in SARD expenses provided more benefit than the drop in pricing versus a year ago. Guillermo noted earlier that a full-year adjusted EBITDA margin north of 30% has never happened before at Life Sciences. That achievement underscores how we've concentrated on strategy, executed with discipline, and built a sturdy margin base. Now please go to Slide 10, where we cover Intermediates. During the fourth quarter, Intermediates kept confronting pressure on both price and volume, with merchant sales along with NMP and BDO volumes down by and large compared with the prior year. Profitability took a further hit from reduced production volumes, and fierce competition stemming from Chinese oversupply plus exports continues to be a major force in the market, especially across Europe. BDO's pricing is still sitting close to the bottom of its cycle. We recorded $33 million in sales, which is an 8% drop versus the same quarter a year ago. Of that total, merchant sales accounted for $23 million, while captive BDO sales came in at $10 million. The main reasons for the decline compared with last year were softer pricing across the board and reduced merchant volumes. Adjusted EBITDA for Intermediates was $5 million, a 15.2% margin, compared with $10 million and a 27.8% margin during the prior year. Margins came under pressure both quarter over quarter and against last year, driven by weaker pricing and lower production. The team keeps running the business carefully, emphasizing efficiency as we work through a difficult market. At this point I'll hand things over to Jim for the Personal Care section. Jim?

Jim Minicucci executive
#5

Thanks, Alessandra. I want to walk you through what happened in Personal Care. For the fourth quarter, sales in that segment came in at $151 million, which is a 7% decline compared with the same period a year ago — and that's mainly because we divested the Avoca business. If you look at it on a comparable basis, though, Personal Care actually posted 5% sales growth, with solid volume gains, and that put us ahead of a market that's holding steady but not doing much. The team did a good job executing, and we saw growth spread broadly across every end market and region. As we anticipated, both of our globalized business lines turned in strong growth this quarter, and they're positioned to keep that going as strategic investments, innovation and a refreshed commercial approach keep building momentum. In biofunctional actives, sales rose by double digits. That performance came off a stable base along with a number of new customer launches that use our innovative actives. Microbial protection posted its fourth straight quarter of sequential growth and got back to healthy year-over-year expansion. Europe saw robust growth, and every region landed major customer wins; on top of that, our commercial excellence work in the care ingredients portfolio keeps paying off in both hair and skin care across regions. Personal Care also moved its innovation pipeline forward with 2 new product launches built on the transformed vegetable oils platform. Now on to profitability. Adjusted EBITDA came to $43 million, versus $47 million a year earlier, which works out to a margin of 28.5%. The drop from last year was mostly the result of portfolio optimization, which cut EBITDA by $7 million. If you set that aside, adjusted EBITDA rose $3 million, helped by higher organic sales and partly held back by lower pricing. To sum up, Personal Care turned in strong growth, profitability that held up well, and clear traction on our strategic priorities, which gives us a solid base for further improvement in fiscal year 2026. At this point I'll turn things over to Dago, who will go through the Specialty Additives results. Dago?

Dago Caceres executive
#6

Thanks, Jim. If you could go to Slide 12. In Q4, Specialty Additives posted $131 million in sales, a 9% drop compared to the same period last year, and in line with what we saw in Q3. We exited low-margin construction business, which took roughly $4 million, or 3%, off sales. If you set those actions aside, segment sales were down 6%, which speaks to ongoing coating softness in China, tough competition in export markets like the Middle East, Africa and India, and weaker demand across North America. The bulk of the volume decrease came from the share loss we experienced in China last year, where too much capacity and sluggish demand keep pressuring volumes and making competition sharper. Coatings demand stayed weak, but sequentially most regions held sales steady. Performance specialties, construction and energy beat the market, helped by our share gain initiatives. Pricing held steady versus a year ago, and foreign exchange gave sales a favorable $2 million lift. Adjusted EBITDA came in at $29 million, flat against the prior year and $3 million higher sequentially, since favorable cost offset lower volumes, producing the year's best margin at 22.1%. Portfolio optimization actions cut EBITDA by $1 million. Setting that aside, adjusted EBITDA rose $1 million on better cost efficiencies, which delivered the strongest margin performance of the year. After closing HEC production in Parlin, we rebalanced the network and put priority on high-value applications to keep margins steady in a weaker demand setting. Going forward, Specialty Additives is positioned well to take advantage of a coatings recovery, which should drive outsized margin gains as demand gets better. With that, I'll hand the call back to William for some additional commentary. William?

William Whitaker executive
#7

Appreciate that, Dago. If everyone could move to Slide 14. With fiscal '25 now behind us, I'd like to call attention to the substantial strides our teams have made. Our $30 million restructuring effort is finished, and it produced $20 million of savings in the year, with an additional $12 million anticipated during fiscal '26. The $60 million program to optimize manufacturing is progressing nicely, delivering $5 million of savings in the year and an expected $18 million in the next one. Fully shutting down Parlin and bringing our HEC operations together marked a significant step forward. The cost measures in VP&D keep moving ahead, and our fiscal '26 run rate objective stays within reach. We've likewise shut 2 smaller facilities as part of consolidating, and that work should wrap up in fiscal '26. Gains in productivity keep coming throughout the VP&D manufacturing chain. As has been — as we've communicated all year long, strategic initiatives are mostly where we want them, yet P&L realization is taking longer than we first assumed, which mirrors today's operating realities. To begin with, cost gains are making their way through more slowly because of weighted average inventory accounting along with higher inventory levels connected to consolidation and tariff mitigation. The timing we originally assumed turned out to be too ambitious, so we're making adjustments. Next, unit costs are being affected by higher expenses at our consolidated site, partly linked to the accelerated HCC time line. We're working hard to tackle these pressures. And third, reduced Asia Pacific volumes have brought plant loading down. We've moved network volume around to keep utilization up, but that has meant less U.S. production and fewer additive savings. All told, the benefits from manufacturing network optimization should land somewhere between $50 million and $55 million given present conditions. We still aim for the entire $60 million opportunity, which stays attainable once China volumes bounce back. Even with revised timing, the program is already helping margins and continues to be an important lever for improvement down the road. These steps are bolstering our cost position and aiding margin expansion. We stay nimble when market shifts occur, and our restructuring moves are already assisting in countering weakness in certain end markets. On top of that, we're upgrading our financial systems and forecasting abilities so we can be more accurate, promote accountability and boost operational performance. Going forward, our priorities are straightforward: wrap up the cost savings program and keep pushing productivity and operational excellence across our leaner footprint. That said, I'll hand the call back to Guillermo. Guillermo?

Guillermo Novo executive
#8

Let's turn to Slide 15. I'm proud of how resilient and agile Ashland has been as we wrap up fiscal 2025. The teams exceeded the innovation targets we'd set, kept advancing our globalization strategy, and in Q4 that strategy began delivering results we could see; across the year, as those investments gained traction, our globalized platform showed consistent sequential improvement. Although the base business was down versus the prior year in the globalized Personal Care segments, the fourth quarter marked an inflection point, posting double-digit growth; for fiscal 2026, we have well-defined objectives to keep that momentum going and build on it. Regarding the innovate strategy we follow, the objectives for innovation that we established were exceeded by our teams, with progress in core technology serving as the driver. During the Innovation Day event held recently, we demonstrated how the new technology platforms essential to Ashland's potential over the long term continue to be reinforced. Growing enthusiasm surrounds our pipeline for innovation, and the momentum we have gained makes us pleased. Our confidence in the portfolio's long-term worth is bolstered by these results. Moving ahead, targets will continue to be shared by us in a transparent manner. In our pursuit of high-quality growth, we consider transparency regarding these goals to be vital. We believe in being transparent about what's working and what isn't — that's the foundation for trust in our strategy and for giving you a realistic picture of where we stand and where we're headed. Looking at fiscal 2026, our goals include $20 million in incremental globalized sales and $15 million in growth driven by innovation, as we scale our platforms and push forward with recent launches. Let's turn to Slide 16. Heading into fiscal 2026, we're staying focused on planning with discipline and maintaining steady leverage. This is the second quarter in a row that we've delivered on our EBITDA commitments, which is a meaningful step in establishing credibility as we enter the new year. The outlook we're providing rests on conservative assumptions and continues to prioritize strong execution, consistency, and transparency. A key point is that our plans now assume we get back to growing, which points to a favorable change in direction and fresh momentum building across all of our businesses. For the full year, Ashland anticipates sales between $1.835 billion and $1.905 billion, which works out to organic growth in the range of 1% to 5%. There's very little in the way of portfolio resets — only about $10 million, coming from the fact that we owned Avoca during the first quarter of fiscal 2025 — which makes this year's numbers simpler to compare against. We're expecting adjusted EBITDA in the range of $400 million to $430 million, along with free cash flow conversion at 50% and capital expenditures of roughly $100 million. That combination delivers an appealing free cash flow yield and gives us room to deploy capital as we see fit. For the coming year, our guidance calls for adjusted EPS to increase by double digits or more, and to do so at a notably quicker pace than EBITDA, with the gains coming from operational enhancements and reduced depreciation tied to portfolio optimization. The assumptions behind our plan take into account the market conditions as they stand today. In Life Science and Personal Care, demand has stayed steady, with innovate and globalize momentum providing support. Meanwhile, Specialty Additives and Intermediates, Specialty Coatings are still under pressure. Macro variables such as interest rates and housing turnover might help spark a rebound, but we have dialed back the upside in our forecast; through share gains, innovation and disciplined execution, we anticipate beating the markets we compete in. Uncertainty tied to tariffs remains; we are managing sourcing, production and logistics and pricing in an active way. As for our input costs, they are stable — raw materials are holding consistent and supply chains are running without disruption. On the cost front, our program for optimizing the manufacturing network keeps moving forward. The majority of plant actions have been finished, and we're still positioned to achieve between $50 million and $55 million in savings given the current environment. The complete $60 million opportunity remains achievable and intact as China volumes bounce back. As William pointed out, shifts in timing will lower the impact during fiscal 2026, though the contribution is still significant. The main elements baked into our 2026 guidance include roughly $30 million of restructuring and network optimization tied to our $90 million program. Around $20 million connected to resetting performance-based compensation and merit increases, plus an approximate $10 million effect from repairs and operational and working capital efficiency efforts across the network in the wake of the Calvert City outage. We're also boosting our R&D spending by $4 million to speed up innovation in a few of the top disruptive opportunities. All told, our fiscal 2026 guidance captures a cautious assessment of market conditions. We're staying committed to pushing innovation forward, expanding globalized platforms and propelling cost and productivity programs to back high-quality growth even when markets are muted; through steady execution, better mix and disciplined capital allocation, Ashland is set up well to produce resilient results and build long-term value. Kindly flip to Slide 17. To wrap up, I'd like to call out several important priorities as we peer ahead. Fiscal year 2025 wrapped up positively, with our teams hitting operational and strategic targets in spite of a tough macro backdrop. Finishing our portfolio optimization and network consolidation has turned Ashland into a more concentrated, durable business, positioned well to grow in high-value markets; we head into 2026 carrying momentum. Cost initiatives are producing early margin improvements, with the complete P&L benefit anticipated to come later. Innovation continues to be a growth driver. Our attention is on speeding up commercial wins. Fresh investments are generating renewed momentum across our globalized platforms, bolstering our belief in the long-term possibilities. For fiscal 2026, we've laid out clear goals: we'll deliver on safety, profitable growth, free cash flow and asset returns; we'll keep advancing network optimization and inventory performance; we'll accelerate innovation; we'll scale globalized platforms and foster a productivity mindset; we'll strengthen systems such as S&OP, costing and planning while applying AI; and we'll prioritize talent and organizational stability, engaging our investors through transparent, dependable execution. The coming fiscal year is about converting transformation into durable results. With a simplified platform and a resilient core, Ashland is set up to generate greater value for everyone with a stake in the company. Through tough periods, our core businesses have remained steady, and we've improved our margins while lifting our asset returns. The groundwork we've laid gives us confidence as we chase our strategic priorities. Thanks to everyone on the Ashland team for your resilience and collaboration. We're intent on turning opportunity into results. Operator, please open the line for Q&A.

David Begleiter analyst
#9

Guillermo, regarding volumes, how did they perform in Q4? And what's the reason your volume assumptions sit at the high and low ends of next year's EBITDA guidance range?

Guillermo Novo executive
#10

Appreciate the question. Turning to volume, we saw a fairly good uptick. Life Science and Personal Care were the main contributors. Looking at SA, particularly coatings, it likely varied by region. For the coatings segment, you need to examine each region separately. A few were higher, a few held steady, and a few declined. China clearly posted the largest year-on-year drop; and Intermediates didn't bounce back; it leveled off. In my view, pricing was the toughest piece there, with some volume effect, but price was the more significant problem. When we think about what lies ahead, what puts us at the lower or upper end? At the upper end — meaning half the growth in our target, at our midpoint — globalize and innovate contributes roughly 2%; so at the midpoint we're only counting on about 1% from market growth or share gains within the market. The low end reflects a market that turns muted and rising competitive intensity that would eat into our globalize and innovate growth. The upside reflects a stronger recovery across some of the markets.

David Begleiter analyst
#11

And regarding the timing pattern for the coming year or the current one, is it expected that Q1 EBITDA will rise compared with Q1 of the previous year?

William Whitaker executive
#12

Yeah, David, this is William. There are several shifting factors when you set things against last year. During fiscal '25, we accelerated a great deal of maintenance work, as you may remember; that created a $25 million drag in the prior year. The first quarter is generally when we carry out much of our yearly compliance shutdowns. So roughly 50% of that falls in this year, around $12 million. Yet we've also told you about that Calvert City outage; that brings a $10 million effect in Q1. So when you weigh the pluses and minuses on the manufacturing side, my expectation is that sales volume will align with what we've described for the guide regarding the year-over-year comparison. Life Sciences ought to show a favorable comparison for sales volume in Q1 relative to the earlier year. And pricing patterns have remained steady. Thus pricing on a year-over-year basis should represent a smaller headwind. So taking everything into account, we're approximately level, slightly up or down against the previous year; however, I'd note that the crucial piece of this is the Calvert City move that we discussed late last month.

John McNulty analyst
#13

Regarding Life Sciences, you mentioned certain softness on the nutrition side, and you also brought up some wins that should help counterbalance it. Could you expand on both a bit further, I suppose? Which areas showed that softness in nutrition? Which business lines, or portions of the business, came in somewhat weaker? And then also tell us what generated those wins? How should we view that in relation to the momentum you're building there?

Guillermo Novo executive
#14

John, let me have Alessandra address that question head-on.

Alessandra Assis executive
#15

Right, so the softness was primarily in North America and Europe. In Europe, it involved one of our customers losing market share. But as Guillermo said, and I also noted in the prepared remarks, we are picking up some momentum through share gains. This is mainly tied to Klucel, and we'll see that show up in our results over the next few quarters, though we expect the recovery to appear as early as the first quarter.

Guillermo Novo executive
#16

As for the share gain we achieved, that has already begun — it's already — orders have already come in, and the effect is already there. So it isn't something still ahead. It's already been won.

John McNulty analyst
#17

All right, understood. That's useful. Then I have one about cash flow. CapEx is now planned at $100 million. How much of that would be growth CapEx, I wonder? At your big Innovation Day, you pointed to several pillars, and a few of those will require capital while others won't. So how much should we factor in for growth CapEx connected to those innovation pillars that appear fairly near to turning the corner and beginning to commercialize?

Guillermo Novo executive
#18

Let me give a fast remark, and William, you can add a bit more detail. The main drivers will be items related to globalize, where we're still putting money into India and merely wrapping up certain projects in Europe. Also, I'd mention that with the HEC projects we completed, exiting Parlin, we're spacing out investments since demand happens to be somewhat softer, yet a few capital projects will be added by us to boost capacity in the U.S. Because things are a bit more muted, we'll handle that at a slower pace, though those remain in the plan. William, would you like to provide a bit more detail?

William Whitaker executive
#19

Absolutely, John — that's a solid question, and it ties directly into the approach we're taking on the asset side. To start with CapEx: our maintenance CapEx is decreasing. Once we rightsized the footprint, stay-in-business capital dropped by roughly $15 million. That means of the $100 million, $55 million goes toward staying in business. Beyond that, there are a few cost-saving moves we want to make that remove bottlenecks from the plan — that's roughly another $15 million. Then, to reach the full $100 million, we have the growth projects, and as Guillermo mentioned, those back the globalized initiatives. More precisely, microbial protection and the OSD tablet coatings business together bring us to $100 million. Looking ahead, regarding your question about new technology platforms, we've already factored that into the plan. A crucial piece for us there is: as we rightsize the footprint, what opportunities exist to repurpose those assets down the road for optionality. So at this stage we aren't carrying any significant — what I'd call a significant bridging item, since we can access that capacity efficiently through the internal assets we've already rightsized.

Chris Parkinson analyst
#20

If we just pause and examine the Personal Care sector, skin and hair numbers look fairly strong; even so, a number of your clients sound upbeat regarding premium buyers while downbeat on the value end. In certain instances, there are indicators of recovery across Asia after an absence of several years; yet the broad picture still appears quite uneven. Would you say that matches what you typically hear? And in the short run, how do you view that, compared with how you view the growth algorithm against the market for your portfolio across the medium to longer horizon?

Guillermo Novo executive
#21

Chris, I'll have Jim address that more thoroughly. Still, there is substantial disparity based on which — the categories you compete in and the geographies; thus variation is considerable. You can observe this in certain earnings calls held by other companies, with some rising in North America while falling in Europe. So quite a bit of fluctuation is occurring. It truly hinges on your business profile, which customers, which categories you serve. Therefore in our case, Jim, please share how this impacts us.

Jim Minicucci executive
#22

Okay. Thank you, Guillermo. Chris, perhaps I'll begin with the final portion of what you asked regarding the short term, then move on to the medium and longer term; when we examine our company and everything we've communicated about our initiatives and our push to globalize and innovate, we believe there are numerous levers available to us within the portfolio. Across a range of segments, we hold a very wide product lineup where we're able to beat the market. That represents how we see things over the medium to long haul. Now, regarding what the market is showing us at this moment, I believe you described it accurately. Conditions are mixed, and where you stand with your customers can heavily influence the results you get; if we take a fast trip around the globe, North America looks somewhat mixed. During Q4, performance there held steady compared with the same period a year earlier, with skin and hair remaining quite resilient; in Europe, we've observed steady strengthening across the year, which carried into Q4, particularly in skin and sun. Looking at sell-in against sell-out, that channel has genuinely gotten better in the sun care market now that inventories have declined, and we've recorded solid expansion in our film formers within sun care. Over in Asia, and in China especially, we've kept our attention on local regionals. As you pointed out, we're witnessing stabilization plus a bit of growth in the prestige segment too; and in that region, our biofunctional actives business delivered very strongly across our other segments within skin and hair; turning to Latin America, I'd characterize Brazil as somewhat mixed at present. Skin performed very strongly while hair is somewhat mixed. Meanwhile, both Mexico and Argentina posted strong results in personal care and home care. Regarding our company in particular, what I would say is—and we've discussed this all year—our 2 globalized business lines, biofunctional actives and microbial protection, have received an enormous amount of effort. The team has performed excellently in truly pushing the commercial work there, and we've achieved great success landing new customer launches with our biofunctional actives along with share gains in our microbial protection. To be specific about biofunctional actives, as we've communicated, that portion of the company has felt the effect of certain customer-specific headwinds; we've now lapped that. Just as we stated on the previous call, it has stabilized, and we anticipate some incremental growth there; and now the new customer wins are beginning to show up externally, having previously been obscured. In the same way, for microbial protection, the base has stabilized and the new wins we've converted over the course of the year are flowing into our results, and we expect that to keep going as we enter fiscal '26.

Chris Parkinson analyst
#23

Understood. Then a brief follow-up regarding a few of those items. On Life Sciences. During your prepared comments, you referenced, I mean, growth in the low single digits, and it feels like this breaks into two parts. First, can we get confirmation that we've at last moved past many of those other sorts of headwinds we're seeing involving a European rival? Second, you note that expansion was driven by cellulosics together with injectables. Is that simply coming off an extremely, extremely sluggish base? Or does some new product account for it? And it would help a great deal just to hear how you'd view the split between cellulosics and injectables growth across the medium to longer horizon.

Guillermo Novo executive
#24

So Chris, cellulosics has consistently been a strong area. So there are fluctuations. It's likely more tied to customer orders and inventory, but not — I mean, those operations have been delivering. Our problem sat more with VP&D, and that part has settled down; but Alessandra, would you like to add a bit more detail?

Alessandra Assis executive
#25

Absolutely. And all three—cellulosics, tablet coatings, and injectables—fit squarely with the approach we've taken, centered on positioning ourselves to expand globally and bring new ideas forward, which is how we pursue growth. Taking injectables first: we've stayed steady, turning in results ahead of the market's pace. We introduced—during the prior quarter's call, we mentioned the resorbable polymers for medical devices aimed at the medical field, which just came out last month; and for injectables we rolled out vialose sucrose, broadening what we can offer through high-purity stabilizers meant for demanding biologic uses. So in essence, injectables within our globalization push have been beating the market, and we've posted solid growth, reflected not just in revenue figures but, just as crucially, in our pipeline—our sales pipeline measured in dollars and in customer programs climbed by more than 30% during the past year versus the prior year. Turning to tablet coatings, we're noticing traction plus efficiency improvements at our production site. We shared that we're putting—we put money into Brazil. That new site opened in April; we also run a site in China. There's a site in the U.S. And we're constructing another site in India. So we're witnessing that traction through double-digit growth year over year, particularly during Q4. That applied to injectables as well as film coatings, which we view as globalization, and it was quite robust, with the film coatings pipeline also expanding well. And like Guillermo said, cellulosics falls under our innovate pillar. It counts toward our innovation metrics, and we've posted solid growth there too. All in all, for Life Science, we beat our goals on the innovation front, and that was truly powered by uptake of high-purity solutions spanning not just OSD through cellulosics, but injectables as well.

Guillermo Novo executive
#26

Can you comment on the VP&D stability?

Alessandra Assis executive
#27

Right. So regarding VP&D — your question was about how things stand versus that rival, and a while back there was some turmoil in the market. Correct, that has settled down. At present, then, whether you look at volume or at price, things are steady right now; the contract season over in Europe is just getting underway. So a bit of movement either up or down is possible, yet as of now, it's holding steady.

Steven Haynes analyst
#28

I'd like to, I suppose, ask something further regarding the pricing matter in Life Sciences. Could you perhaps give us some detail on the share of your — I guess, book, or whatever way you'd prefer to describe it — that comes up for renewal annually when it comes to price contracts?

Guillermo Novo executive
#29

The precise business mix and customer breakdown isn't something we discuss. Still, I'd say the bulk of it — the larger factor is Europe. In Europe, a number of the bigger participants, they have a tendency to do this simultaneously. So everything would be included, VP&D, cellulosics. That means the whole portfolio. You sign contracts covering every product in that region. And clearly, looking at it from a sales standpoint, cellulosics and VP&D make up the largest portion of the mix. Tablet coatings and injectables would be the more recent items, using technology that's quite different.

Steven Haynes analyst
#30

All right. Then perhaps to follow up on that, the $4 million in extra R&D spending you called out in the guidance — was that R&D spending sort of in your plan to begin with? Is it getting pulled forward? And could you give us a bit of detail on where that additional spending is headed, in terms of the various platforms you pointed to at Investor Day?

Guillermo Novo executive
#31

Yes. Like we pointed to at Investor Day, there are two things as we launch these and work alongside customers and develop the two questions: investment for manufacturing, the CapEx; and luckily, we have capital we've idled that we're able to repurpose, and that's where the focus is; but the other piece, simply an acknowledgment that, hey, as these things truly begin moving, we'll likely need to bring in resources to actually develop the products, depending on what the customer is after or the applications. At the moment, most of that sits with the new technology platforms. The TVO, the transformed vegetable oil, is the one with the broadest legs. If you look at it, it's going into practically every business in Life Science, in tablet coatings, in ag, it's reaching lots of areas across many, many applications in personal care and in coatings; so we're bringing in both resources. We're working to bring in resources so we can scale this capacity. So not every business has to double the work; so right now, some of it will be in the coatings area. We have some genuinely exciting technology developments with TiO2 efficiency and with alkyds and a few other areas. So on the polymerization side, we're bringing in some of the capabilities that will assist all the businesses, but we're centering it there since that team is a bit more focused and we have more capabilities there. And then another piece of it, we're doing on our central R&D, again, to support — there are more requests from customers for modifications. The core technology, we're getting validation. What's at issue now is converting them into specific products that our customers want. And that will require a much greater engagement with customers. So that's what we're going to bring in. But we're going to pace ourselves. As we said, we're not going to simply throw R&D; we want to see where things are advancing and then we will drive the investments. I think on the other areas like super wetters and pH neutralizer and all that, we are — we've brought in resources, but it's really been more shifting within the businesses of people that they had on other projects supporting them as they go. So we'll be providing more color on the innovation side.

Jeff Zekauskas analyst
#32

My understanding is that you were anticipating $100 million out of your innovation pipeline in 2027. What are you looking for from that pipeline in 2026?

Guillermo Novo executive
#33

When it comes to '26, what we've laid out at this point is $15 million in new innovation, and that's still largely core. As for the launches, like we mentioned during the Innovation Day, the newer technologies would likely begin more in the '27-and-later timeframe, simply given where things stand with customer developments.

William Whitaker executive
#34

And Jeff, when we talk about that target, it's cumulative when it comes to incremental sales. So this year we delivered $13 million, and then there's the $15 million on top of that, which puts us at roughly $30 million — that's the cumulative commitment as of now, measured from the Strategy Day through '26.

Guillermo Novo executive
#35

And to clarify as well, Jeff — on the globalized part, we've really kept things very straightforward. For globalized, we simply placed all of it in there, so it includes things like injectables. There's a great deal of innovation in that space. Our goal was to present a really clear narrative since our investment approach in globalized differs. There are assets involved. There are other matters we have to handle. They're quite distinct across each of the areas. That way, you basically receive the complete — the net view of how that's performing. Tablet coatings, biofunctionals, and microprotection all have substantial R&D and technology activity underway. So at this moment, what we refer to as innovation consists of core plus the new technology platforms that don't belong within those 4 segments.

Jeff Zekauskas analyst
#36

Alright. Regarding your cash flows, I believe you mentioned expecting 50% conversion in 2026. Is the $100 million you got as a tax refund part of that figure? And when it comes to your inventories, they seem to have risen from roughly $530 million at the start of the year to around $570 million by year-end, despite sales being down, I think, 15%. So, do you need to reduce production to bring inventories down to a more sensible level?

Guillermo Novo executive
#37

Would you like to take the...

William Whitaker executive
#38

Yeah. So Jeff, with regard to that 50%, the $103 million tax return isn't part of it. Just to help you picture the bridge, okay? It starts from the midpoint of EBITDA. Cash taxes, cash interest, and working capital don't shift much across the full year. There's definitely a chance here, right? In Q1, VP&D will see a release of $16 million to $18 million tied to the Calvert City outage. And then at HEC too, right? We shut down Parlin, and ahead of that we stocked up on inventory to smooth that transition. So we do view inventory as an opportunity; for the past couple of years we've typically run at 2.5 turns. But when it comes to meeting that 50% commitment, it's roughly the same as keeping working capital flat; so as sales rise, we'll naturally put money into accounts receivable, though some of what we're doing on inventory will provide an offset.

Guillermo Novo executive
#39

And Jeff, regarding inventory, there are 2 main categories that ticked up somewhat. First is HEC. When Parlin shut down, we had to—that was always in the plan. We needed to accumulate stock since we must transition during the startup phase. The new facility has to be qualified. So we stockpiled sufficient inventory; it will decline. Shutdowns aren't the issue anymore. As for the HEC network, to be completely clear about the total, since that's likely tied to network optimization, the dollars being pushed to next year really center on the HEC network. Several factors are at play. First, our flow-through average accounting—meaning our estimate is probably a bit too optimistic in certain areas. That factors in. I believe the inventory buildup plays a role there. So it gets pushed back somewhat. But more significantly, I'd say this: the benefits exist. The plant is shut, correct? So we do have that benefit. Roughly 2/3 will flow through this year and next year as we progress. The remaining 1/3, I believe, arrives later. It hasn't vanished. That's the piece where, given weaker demand in China, we've rebalanced our network. The network is now fairly loaded even in a down market; so our operations are far more steady. However, we moved volumes we used to prefer making in the U.S. over to China, and now China—our facility there is exporting to other regions globally. So the network has been rebalanced. In my assessment, the one I'm focused on is that about 1/3 of their HEC target will likely be postponed until China rebounds and we can bring that volume back to the plants we'd originally intended. China is bottoming out. It remains soft. It's still intensely competitive, but we're beginning to see chances to capture share and shift some volume upward, though it will require—it's going to be a gradual climb from here.

Laurence Alexander analyst
#40

I have 2 things. First, regarding what you said about competitive intensity, especially coming from Chinese rivals, is that pressure concentrated in the same steady set of areas? Or is it spreading into additional portions of your portfolio? Second, when it comes to the innovation pipeline, could you provide some flavor of the horse race — which platforms are your customers telling you matter most, even if those platforms are on a slower burn?

Guillermo Novo executive
#41

Yes; regarding your first question, China competition, for us it truly is the same areas. I realize this is a wide theme across many companies; in our case, it has mostly been VP&D and HEC. From where I sit, those two situations aren't the same for our company. In the first case, you've got worldwide rivals who are shipping product out of China. They've got several facilities running. That means when we say China, we're not just talking about domestic Chinese companies — we're talking about China as a source of supply. Given how much volume moves through this market, we're essentially the final major producer outside China across many of these segments. That's the pattern we're seeing in VP&D. When it comes to HEC, my read is that it's partly too much capacity sitting in China, but it's also the weak market, and exports have gotten quite aggressive. The bulk of what we're noticing is concentrated in the Middle East, Africa and India — those are the regions where it's shown up most. When we talk about where the strain is coming from and where our exports out of China will go, our plan is to maintain China's operations for the Chinese market while also serving regions like the Middle East, Africa, and India. Turning to innovation, demand exists across the board. In my view, transformed vegetable oil technology offers the most functional versatility. That means we'll be heading in quite a few distinct directions. Just compare what Life Science, pharma, or ag players focus on with what those in personal care and coatings are after. When every one of these players keeps pushing their tech forward and adding new capabilities, we're able to take those same advances and bring them into additional markets, which is a big advantage for us. That's the area I believe we'll be concentrating on most — specifically, the question of how we achieve scale. To get there, we have to narrow our attention onto a handful of the larger opportunities, since building scale requires that kind of focus. Down the road, as I mentioned during Innovation Day, this technology is closer in nature to something like acrylics — it has the potential to reach a far wider scope. So that's exactly why it draws so much attention. On the additives front, especially the super wetters, I'd put those in the additive category. Honestly, it has amazed me how many fresh uses the teams have come up with by tweaking them. We're moving into agriculture. We just launched in Brazil, and as we shared, we're also in bioprocessing and personal care, where there are some genuinely exciting openings in both skin and hair. Coatings could be a sizable, highly scalable opportunity too. Those are the areas I'd say we're quite excited about. Starch is another one that's performing very well, mostly in personal care, though I think it will eventually carve out a role as we keep exploring Life Science.

John Roberts analyst
#42

Could you assist us in distinguishing seasonal patterns within the Specialty Additives segment versus the underlying trajectory? That 6% drop you reported for the September quarter was basically entirely volume-related. Assuming conditions have settled back toward typical levels, we'd be looking at a 6% decrease in the — I realize you're not inclined to provide specific guidance for the December quarter, but does that represent a straightforward comparison, that negative 6% that returns to normal? Or do we continue to see a downward drift beneath the underlying trajectory?

Guillermo Novo executive
#43

Well, let me offer a few remarks, and afterward I'll invite Dago to weigh in. As I mentioned, the response will differ depending on the region. Obviously, North America is the area where we've observed — it's not that the market itself is declining, but our customers' expectations have diminished, in both DIY and contractors. My sense is China is a different situation. It's declining, and there's no recovery happening. Those would be, in my view, the 2 major ones. But Dago, could you provide some additional detail?

Dago Caceres executive
#44

Yeah. Well, that's a really solid question. So here's what I'd say — if I take stock of our position, honestly, in China we aren't seeing a recovery, and I wouldn't expect one over the coming 1 or 2 years. Why is that? Because China has to work through structural problems that must be resolved in the property sector, and we keep observing a slowdown in property investment, and that sector is a major force behind the coatings market there. So some softness will persist. My sense is it's bottoming out more, yet we'll still face a degree of weakness, I'd say, heading into 2026. Then if you consider North America, the main forces in coatings markets, I'd argue, number two. One is home sales, which could be existing homes or new construction, plus what you might call the repaint, remodel type of market, correct? And home sales, whether existing or otherwise, get pushed by interest rates and by housing prices; and rates remain comparatively elevated, and housing prices remain comparatively elevated too. So my view is it won't be — there is — that explains why the market shows some caution regarding those two; yet on the repaint and remodel side, the do-it-yourself segment, that one stays fairly flat. Pricing is a touch better, though it isn't truly gaining much momentum. If you talk to our customers, if you listen to what the market signals, they largely lean toward this belief that perhaps the first half of 2026, calendar year 2026, will be weak given these conditions; that said, I've been caught off guard before, the market could bounce back, could strengthen if construction activity strengthens, and we must be prepared for that; however, at this point, what we observe is Europe holding fairly steady. North America is steady. China, we know that story; and then there will be competitive pressure in the Middle East, Africa, India and rest of Asia that we've been handling more or less across the past year.

Guillermo Novo executive
#45

And John, I'd say the positive side that nobody should give up on is North America, where there's built-up appetite for houses, building, that sort of thing — but that's a macro factor outside our hands. So right now, we're going to go along with whatever our customers tell us.

Josh Spector analyst
#46

To start, I'd like to ask about pricing. On the Life Sciences side, you already addressed this earlier, noting that things appear to be stabilizing. However, regarding Specialty, you mentioned that pricing was flat compared to a year ago, yet I believe you hinted at the possibility of greater pressure. Are you thinking about that primarily in terms of volume? Or do you still anticipate some pricing downside as you look ahead to fiscal '26?

Guillermo Novo executive
#47

Let me just make one remark, and my own perspective is that pricing, and where pressure shows up, is China and exports, which are so low right now. No one is earning money. Eventually there is a floor. It cannot keep dropping; at some point it isn't worthwhile. So I do believe there is a degree of stability. The problem will be more about export markets, and that's the entire matter, I think, regarding the effect on exports to Europe and all of that, which we are observing across various products, not only SA, but in other segments too. But would you like to add a bit more?

Dago Caceres executive
#48

How I'd frame it is that North America, and really the US, should see fairly steady pricing. Europe, I'd say, looks much the same; those two are our biggest markets; in both, volume and price are behaving in the usual way, though I'd call them fairly steady compared with fiscal year 2025. And those, again, are essentially our two main markets. As for everywhere else, we're simply proceeding cautiously and we always weigh volume against price to figure out where keeping prices where they are makes sense, and we do this continually; that's the reason our pricing didn't decline last quarter, or when we choose to chase particular share gains, right, or when we want to improve the balance of the network. So in 2026, I'd expect we'll keep seeing some pressure, particularly in places such as the Middle East, Africa, India, though I'd say it looks much like what we've seen up to now. And the encouraging part remains that what we offer is greatly valued by customers. They appreciate quality, they appreciate innovation. They appreciate the value proposition we provide as a whole. So our belief is that with the right mix, I mean, we can retain what we've got.

Josh Spector analyst
#49

And real quick, Guillermo or William, I mean, what do you two think about capital allocation at this point? Is lowering leverage a prerequisite before you'd consider restarting buybacks? Or might that be something you'd look at doing sooner?

Guillermo Novo executive
#50

I'll have William provide the finer points, but flexibility is something we have today. As William mentioned during his remarks, doing both is possible for us. Our approach will stay pragmatic, consistent with how we've operated previously. There's clearly a value angle at the current share price. That said, given the uncertain environment, we also want to balance that against the way we handle our debt. Want to add anything further?

William Whitaker executive
#51

Yeah. Thanks, Josh. So our priorities for allocating capital haven't changed. To start, we'll put money behind the strong organic growth projects — that's part of the $100 million in CapEx — plus the productivity initiative, which matters a lot to us for bringing down costs at the plants. Beyond that, leverage matters. We intend to stay inside our target range and keep the balance sheet flexible. After that, any excess capital — excess cash — goes back to shareholders. Our stated dividend policy calls for a 30% payout. We're running a little higher than that. So going forward, I'd anticipate dividend growth being more modest. Once the dividend is covered, we'd aim for a balanced approach to deploying capital, the way we've done before, with share repurchases happening from time to time. One takeaway from the outlook, I think, is that we do expect solid free cash flow generation over the coming year. So when you carry forward the tax return we just discussed along with that free cash flow, and you deliver the midpoint of the EBITDA guide, we'd be down in the low 2s; that gives us plenty of flexibility, and we'll stay balanced and disciplined in our approach over the next year.

Abigail Edwards analyst
#52

I simply wanted to verify the schedule for the portfolio optimization headwinds. At what point ought we to anticipate those being entirely lapped?

William Whitaker executive
#53

I'm able to handle that. Yes. So Abigail, I believe the positive aspect is that as we move into the following year, it's — there's a slight effect in personal care during Q1. It amounts to roughly $10 million in sales, $1 million in EBITDA, and after that, nothing more. And thus, for the initial time in a good while, it's an extremely clean baseline and our reporting ought to be if we expand 2%, we expand 2%, and there isn't necessarily this adjustment regarding items that we've rationalized or divested previously. So it's an extremely clean setup as we head into the following year.

Analyst analyst
#54

All right, that sounds positive. And I have one more question about timing. You're anticipating a rebound in nutrition during the middle of fiscal year '26 — could be afterward, could be sooner? When exactly do you expect that?

Alessandra Assis executive
#55

Regarding nutrition, like Guillermo said, it's taking place right now in October. Those gains, particularly involving Klucel, have already materialized. We began getting orders near the finish of the fourth quarter of the fiscal year, and we're already shipping items in October, and now November. So it's genuine. It's already underway, and we anticipate seeing nutrition start to close the gap we experienced in Q4. Like I said, that was a share gain by our customer in Europe. Naturally, because of that, we wound up losing share too. But it's Klucel bringing new wins, and this win is profitable.

Guillermo Novo executive
#56

I'd also point out that what's dropping away is largely lower-margin business. The material replacing it carries a stronger margin profile, so on balance the effect will be favorable.

Mike Harrison analyst
#57

I just wanted to dig a bit deeper into the network optimization. What I'm really asking about is the schedule for those benefits you've shifted out; I'm wondering what would have to occur for us to capture some of them sooner. Is it simply a matter of stronger demand? Would that stronger demand need to come from particular geographies or particular product lines? Or are there additional steps? I know you said there might be some incremental VP&D steps. Are there other things you could do that might speed up some of those benefits?

Guillermo Novo executive
#58

Yes. So when you examine the steps, Mike, the small plant represents a lower figure. The bulk of those will be finished in the first half of this year; they'll be complete, and they'll simply flow through. HEC, like we talked about, is the piece generating the bigger flow-through timing problem. And that one involves those 3 stages of, hey, the step is finished. The flow-through assumption based on an average accounting basis was likely overly optimistic, more delayed. But the inventory and the revenue. So sales are going to be the major factor and the major catalyst. If sales improve, we can shift far more of the material. So that flow-through simply speeds up. The piece we do want to be transparent about is part of it, roughly 1/3 of the HEC volume. I'm glad we did it, but it's keeping our position in China from deteriorating. It's now — rather than being incremental, we would have seen a deterioration of our business in China, and this step has already helped it, right? So we're receiving a benefit. It's just not incremental. For it to turn incremental, that's what we mean when we say China has to pick up where somebody else needs to pick up to offset that so that we can rebalance the network. So that's the one with the most timing problems because it's done. I think the VP&D, we're working across. We have several — 2 plants; we worked on one; we're going to begin working on the other one through a lot of steps and timing. So that one, the conclusion of the events will determine the timing of those things.

Mike Harrison analyst
#59

All right. Then my second item was directed at Dago. Could you provide an update regarding the work being done to broaden your applications or possibilities within industrial coatings? My sense is that most of what you said covered the architectural side. So I wanted to ask whether there are any fresh business wins or applications that you're going after.

Dago Caceres executive
#60

Yes, certainly. That's a great question, and it sits very much at the center of our efforts under this strategy, namely innovation. There are a few things we're doing. To start, we're pursuing quick wins. By quick wins, we mean that we already possess a fairly strong portfolio, and what was really missing was application data that could be applied to industrial coating uses. So we're doing quite a bit of that. With the portfolio in hand, our aim is to target those industrial customers. We know their identity, we know the path to reach them, and we have a portfolio that already exists. For us, that's truly a quick win, an area we're examining a bit further in order to speed up monetization of our innovation work. Then over the longer term, there are two parts; it's also the core business. It's also the core portfolio. Beyond that, we have areas such as easy-wet. Take easy-wet, for example — just 2 weeks ago we launched another product, it's ready to go, and we're already witnessing fairly strong traction among our customers. It happens one customer at a time. It's about speaking with customers, making certain their needs are met. Still, I'd say that area is progressing rather well, and we keep uncovering opportunities. I believe the difficulty ahead of us will be ensuring that we stay focused and direct the resources at our disposal toward the right opportunities, where we can achieve a bigger bang for our buck; but it's going pretty well, and hopefully there's more to come on that front. Thanks for asking.

Guillermo Novo executive
#61

Okay, thanks to all of you for joining and for being interested. Like I mentioned, I'd like to give credit to the team — the outside situation has been extremely dynamic, and I believe we've followed through on many of the commitments we made. So that leaves us feeling quite positive. We continue to anticipate that conditions outside the company will stay unpredictable, with a significant level of ambiguity. Both favorable and unfavorable. So there may be some favorable developments too. I don't want to focus only on what could go wrong. It's simply ambiguity. That, I believe, genuinely pushes us to concentrate on what's within our power. Our approach remains appropriate for this kind of situation. The steps we've taken regarding execution and optimizing our portfolio, even when they get pushed back, are assisting us in improving results in the short run and making us stronger across every one of our main businesses. So we're zeroing in on what we can influence: carrying out our portfolio optimization along with productivity and operational rigor; pushing globalization forward and advancing innovation to genuinely grow the top line. And should we accomplish that, we have strong confidence in what lies ahead, even under these conditions. If circumstances improve, there's enormous room for greater utilization of our production facilities and everything that comes with it. So that would truly be the most significant trigger we'd witness when it comes to momentum, should we observe some rebound in the market. With all that said, we're eager to meet with you over the next few weeks, and thank you.

Operator operator
#62

We appreciate everyone joining this call today; that brings the session to a close, so you're free to hang up at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Ashland Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Ashland Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.